Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Worldwide Idiopathic Pulmonary Fibrosis 2016 Analysis and Forecast 2020

Thursday, September 22, 2016 6:14
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Idiopathic pulmonary fibrosis belongs to a group of lung diseases known as interstitial lung diseases. It affects people in the age group 50-70 years. Diagnosis is effected by the exclusion of other interstitial lung diseases. High-resolution computed tomography (CT) is often employed to confirm the presence of the disease. There is no permanent cure for this disease; therefore, treatment involves relieving underlying symptoms. Nintedanib and pirfenidone are the two approved drugs for the treatment of idiopathic pulmonary fibrosis. Corticosteroids and immunosuppressive drugs are also used for the treatment.

Publisher’s analysts forecast the global idiopathic pulmonary fibrosis market to grow at a CAGR of 23.97% during the period 2016-2020.

For more information about this report: .

The report covers the present scenario and the growth prospects of the global idiopathic pulmonary fibrosis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of idiopathic pulmonary fibrosis.

The market is divided into the following segments based on geography: 
- Americas

Publisher’s report, Global Idiopathic Pulmonary Fibrosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 


Make an enquiry: .


Key vendors 
- Baxter International
- Boehringer Ingelheim
- F.Hoffmann-La Roche
- Prometheus Laboratories

Other prominent vendors 
- Afferent Pharmaceuticals
- Amgen
- Biogen
- Bristol-Myers Squibb
- Cipla
- FibroGen
- Gilead Sciences
- GlaxoSmithKline
- GNI Group
- Horizon Pharma
- ImmuneWorks
- MediciNova
- MedImmune (subsidiary of AstraZeneca)
- Novartis
- Pfizer
- Promedior
- ProMetic Life Sciences
- Sanofi
- Shionogi
- Zai Lab

Market driver 
- Unmet medical need
- For a full, detailed list, view our report 

Market challenge 
- Lack of proper diagnosis
- For a full, detailed list, view our report 

Market trend 
- Patient assistance programs 
- For a full, detailed list, view our report 


Buy this Report: .

Contact Us:
Call: +1-646-491-9876

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.